TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.1606
-0.0074 (-4.40%)
At close: Nov 13, 2026, 4:00 PM EST
0.1640
+0.0034 (2.12%)
After-hours: Nov 13, 2026, 7:49 PM EST
TScan Therapeutics Revenue
TScan Therapeutics had revenue of $586.00K in the quarter ending September 30, 2026, a decrease of -76.66%. This brings the company's total for the last twelve months to $5.19M, down -38.43% year-over-year. In the year 2025, TScan Therapeutics had annual revenue of $10.33M with 266.65% growth. That makes TScan Therapeutics the 39,860th largest company in the world by revenue and 5,281st in the United States.
Revenue (ttm)
$5.19M
Revenue Growth
-38.43%
P/S Ratio
2.10
Revenue / Employee
$37,580
Employees
138
Market Cap
10.89M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.33M | 7.51M | 266.65% |
| Dec 31, 2024 | 2.82M | -18.23M | -86.62% |
| Dec 31, 2023 | 21.05M | 7.51M | 55.52% |
| Dec 31, 2022 | 13.54M | 3.39M | 33.47% |
| Dec 31, 2021 | 10.14M | 9.06M | 834.65% |
| Dec 31, 2020 | 1.09M | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 13.19M |
| Radiopharm Theranostics | 8.90M |
| Dyadic International | 3.80M |
| Vyome Holdings | 129.73K |
| Lisata Therapeutics | 100.00K |
| Fractyl Health | 3.00K |
TCRX News
- Just now - TScan Therapeutics Earnings release: Q3 2026 - Filings
- Just now - TScan Therapeutics Quarterly report: Q3 2026 - Filings
- 2 days ago - TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 19 days ago - TScan Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - TScan Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - TScan Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 2 months ago - TScan downgraded to Market Perform from Outperform at LifeSci Capital - TheFly
- 2 months ago - Needham downgrades TScan Therapeutics as company reprioritizes - TheFly